Turn Therapeutics Inc.
TTRX Nasdaq
SEC CIK 2023016
Follow Turn Therapeutics
Weekly email: filings, results
Net income
−$6.2M
−227.2% vs same quarter last year
EPS, diluted
−$0.21
−200% vs same quarter last year
Operating cash flow
−$1.5M
−163.2% vs same quarter last year
Operating income
−$2M
−3.7% vs same quarter last year
Source: SEC XBRL filings · latest filing